Nucala® (mepolizumab) is now listed on the PBS for Australians with chronic rhinosinusitis with nasal polyps

Issued: Monday 3 April, 2023

• Nucala is the first biologic treatment to be PBS-subsidised for the treatment of severe chronic rhinosinusitis with nasal polyps^1,2
• Chronic rhinosinusitis is a common chronic respiratory disease that affects one in ten Australians.³ An estimated 25-30% of people living with chronic rhinosinusitis also have nasal polyps (soft jelly-like tissue growths within the nasal cavity)^4,5
• The availability of Nucala on the PBS for CRSwNP provides subsidised access to a new treatment option for these patients
• Video news release available here.